Preliminary experience with inhaled nitric oxide for acute pulmonary hypertension after heart transplantation

J Heart Lung Transplant. 1995 May-Jun;14(3):419-23.

Abstract

Background: Substantial interest has developed in the physiologic and therapeutic role of nitric oxide in the last few years. In patients with pulmonary hypertension it appears to be a useful selective pulmonary vasodilator; however, many issues of both staff and patient safety remained unanswered.

Methods: This study examines further safety issues and also presents preliminary clinical experience in patients after orthotopic heart transplantation with pulmonary hypertension and right-sided ventricular failure.

Results: Atmospheric levels of nitric oxide and nitrogen dioxide are 100 times less than occupational health standards. When nitric oxide is used at 70 parts per million in the presence of a fraction of inspired oxygen greater than 0.60, nitrogen dioxide levels in the circuit exceed the published short-term exposure limit of the American Conference of Government Industrial Hygienist of 5 parts per million.

Conclusion: Staff safety appears confirmed, but despite encouraging clinical results, further longer term safety and efficacy studies are indicated.

Publication types

  • Clinical Trial

MeSH terms

  • Administration, Inhalation
  • Heart Transplantation*
  • Humans
  • Hypertension, Pulmonary / complications
  • Hypertension, Pulmonary / drug therapy*
  • Nitric Oxide / administration & dosage*
  • Nitric Oxide / analysis
  • Nitric Oxide / toxicity
  • Nitrogen Dioxide / analysis

Substances

  • Nitric Oxide
  • Nitrogen Dioxide